Lexeo 10-Q: $219.1M Cash Funds Operations Into 2028; Q3 Net Loss $38.3M
LXEO sits 25% above its 52-week low of $2.55 on light trading volume (0.3× avg).
Summary
Lexeo reported a $38.3 million Q3 net loss and $219.1 million in cash and investments, which management says funds operations into 2028. The quarter included $9.9 million of acquired IPR&D expense from the Mantle deal and $37.7 million of net ATM proceeds raised over nine months.
Key Events · Earnings and Guidance · LXEO
-
Cash Runway Extended Into 2028
Cash, cash equivalents and U.S. Treasury investments totaled $219.1 million at September 30, 2026, which management says funds planned operations into 2028 — versus the Q3 2027 runway given with the prior quarter.
-
Q3 Net Loss $38.3 Million
Net loss was $38.3 million for the quarter and $84.4 million for the nine months, with R&D up $18.8 million year-over-year to $34.5 million, largely on $9.9 million of acquired IPR&D from Mantle and a $3.5 million Adverum milestone.
-
ATM Raised $37.7 Million Net
Lexeo sold 7,533,881 shares under its Leerink ATM in the nine months at a $5.26 volume-weighted average price, generating $39.6 million gross and $37.7 million net after $1.2 million of agent fees and $0.7 million of other costs.
-
Mantle Deal Adds Up to $30.6M Milestones
The September 29, 2026 Mantle acquisition cost $7.5 million initially, including 632,907 shares valued at $3.42, with up to $30.6 million more payable on development milestones — $28.6 million of it in cash.
Analysis · LXEO · Life Sciences
The balance sheet is the story here. Lexeo ended September with $219.1 million in cash and Treasury investments and now says that funds operations into 2028 — a longer runway than the Q3 2027 guidance given with the prior quarter, and the key question for a clinical-stage gene therapy company burning roughly $67 million of operating cash over nine months. The quarter's $38.3 million net loss was inflated by one-time items: $9.9 million of acquired IPR&D written off immediately from the Mantle acquisition, a $3.5 million Adverum milestone, and a $1.6 million legal insurance reimbursement that cut G&A. Funding came partly from the ATM, where 7,533,881 shares were sold in the nine months at a $5.26 average for $37.7 million net — real dilution, but done at prices well above today's $3.20. With the LX2020 pivotal study not starting until 2H 2027, the runway now covers the period when that spending begins.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LXEO was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $235.6M. The 52-week trading range was $2.55 to $10.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.